ID   MCF-7/TAX
AC   CVCL_IJ26
DR   cancercelllines; CVCL_IJ26
DR   Wikidata; Q54904385
RX   PubMed=24289639;
CC   Population: Caucasian.
CC   Doubling time: 44.60 +- 1 hours (PubMed=24289639).
CC   Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C4194; Invasive breast carcinoma of no special type
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0031 ! MCF-7
SX   Female
AG   69Y
CA   Cancer cell line
DT   Created: 01-12-16; Last updated: 05-10-23; Version: 13
//
RX   PubMed=24289639; DOI=10.7314/APJCP.2013.14.10.6135;
RA   Chen S.-Y., Hu S.-S., Dong Q., Cai J.-X., Zhang W.-P., Sun J.-Y.,
RA   Wang T.-T., Xie J., He H.-R., Xing J.-F., Lu J., Dong Y.-L.;
RT   "Establishment of paclitaxel-resistant breast cancer cell line and
RT   nude mice models, and underlying multidrug resistance mechanisms in
RT   vitro and in vivo.";
RL   Asian Pac. J. Cancer Prev. 14:6135-6140(2013).
//